Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $399.50 | Total: $1,997.50 |
| 1 | 10 | $338.40 | Total: $3,384.00 |
| 1 | 25 | $286.70 | Total: $7,167.50 |
| 1 | 50 | $244.40 | Total: $12,220.00 |
| 1 | 100 | $211.50 | Total: $21,150.01 |
Overview
Marizomib (ML858) is a novel irreversible brain-permeable proteasome inhibitor that inhibits CT-L (?5), CT-T-laspase-like (C-L, ?1), and trypsin-like (T-L, ?2) 20S proteasomes with IC50s of 3.5, 28, and 430 nM, respectively.
Chemical Properties
| Molecular Formula | C15H20ClNO4 |
| Molecular Weight | 313.78 |
| CAS Numbers | 437742-34-2 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | [C@@H](O)([C@]12[C@](C)([C@@H](CCCl)C(=O)N1)OC2=O)[C@]3(CCCC=C3)[H] |
Storage and Handling
0C Short Term, -20C Long Term
References
Di K, et al. Marizomib activity as a single agent in malignant gliomas ability to cross the blood-brainbarrier. Neuro Oncol. 2016 Jun;18[6] 840-8.